The branches of the immune system work in concert to defend against pathogens and
prevent tissue damage due to excessive inflammation. Uropathogens in general,
and uropathogenic
Escherichia coli
(UPEC) in particular, have
evolved a diverse range of virulence mechanisms to avoid detection and
destruction by the mucosal immune system of the urinary tract. Research towards
a vaccine active against UPEC continues but has yet to be successful. Orally
administered immunomodulatory bacterial lysates both stimulate and modulate the
immune response in the urinary tract
via
the integrated mucosal
immune system. The 2018 European Association of Urology (EAU) guidelines on
treating acute uncomplicated cystitis recommend aiming for rapid resolution of
symptoms, reduction of morbidity, and prophylaxis against reinfection.
Recommended short-term antibiotic therapy has the advantage of good compliance,
low cost, few adverse events, and low impact on bacterial flora. Antibiotic
treatment of asymptomatic bacteriuria is only indicated during pregnancy and
before invasive interventions. For recurrent infection, prophylaxis using
behavioral modification and counseling should be employed first, then
nonantibiotic prophylaxis, and, finally, low-dose continuous or postcoital
antibiotic prophylaxis. The 2018 EAU guidelines give a strong recommendation for
the oral bacterial lysate immunomodulator OM-89. All other nonantibiotic
prophylactic strategies require more data, except for topical estrogen for
postmenopausal women. For last-resort antibiotic prophylaxis, nitrofurantoin or
fosfomycin trometamol are recommended. Guidelines for Latin America are
currently being drafted, taking into account the unique ethnicity, availability
of medicines, prevalence of antibiotic resistance, and healthcare practices
found throughout the region.